PACS vs VRTX · P/E 23, rev $5.29B vs P/E 30, rev $3.33B
PACS Group, Inc. (PACS) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
PACS Group, Inc. (PACS) is a medical care facilities company listed on NYSE.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported PACS revenue for 2025-12-31 was $5.29B. Net income was $191.5M. Revenue was up 29.3% from 2024-12-31 to 2025-12-31. PACS currently screens at market cap $5.58B and trailing P/E 22.7.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
PACS currently screens at market cap $5.58B and trailing P/E 22.7. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the PACS and VRTX stock pages for the full models.
Not investment advice.